KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Liabilities and Shareholders Equity (2023 - 2025)

Biocryst Pharmaceuticals' Liabilities and Shareholders Equity history spans 9 years, with the latest figure at $514.2 million for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity rose 4.84% year-over-year to $514.2 million; the TTM value through Dec 2025 reached $1.9 billion, down 1.26%, while the annual FY2025 figure was $514.2 million, 4.84% up from the prior year.
  • Liabilities and Shareholders Equity reached $514.2 million in Q4 2025 per BCRX's latest filing, up from $446.4 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $529.9 million in Q2 2023 to a low of $446.4 million in Q3 2025.
  • Average Liabilities and Shareholders Equity over 3 years is $491.6 million, with a median of $490.8 million recorded in 2024.
  • Peak YoY movement for Liabilities and Shareholders Equity: decreased 10.84% in 2024, then rose 4.84% in 2025.
  • A 3-year view of Liabilities and Shareholders Equity shows it stood at $517.0 million in 2023, then decreased by 5.13% to $490.4 million in 2024, then increased by 4.84% to $514.2 million in 2025.
  • Per Business Quant, the three most recent readings for BCRX's Liabilities and Shareholders Equity are $514.2 million (Q4 2025), $446.4 million (Q3 2025), and $457.2 million (Q2 2025).